Hims & Hers (HIMS) has recently experienced a notable surge in its stock price, driven by excitement surrounding FDA developments in peptide drugs and a strategic partnership with Novo Nordisk for distributing the branded weight loss medication Wegovy. This collaboration positions Hims & Hers advantageously in the GLP-1 market, moving beyond the limitations of compounded alternatives.
The company is ramping up its capital investments in manufacturing capabilities and the acquisition of Eucalyptus, even as it anticipates a significant decline in earnings per share (EPS) for the first quarter. This situation has created a tension between buyers and sellers in the stock market.
Recent Stock Performance
On Monday, Hims & Hers shares rose by 9% in early trading, climbing from approximately $28.82 to over $31 as investors eagerly awaited the earnings report set for May 11. This rally caps an impressive week for the stock, which has seen an overall increase of 49% over the last five trading days, making it one of the most dynamic stocks in the market ahead of its quarterly results.
Two primary factors are fueling investor enthusiasm. The renewed FDA focus on peptide drugs has sparked optimism regarding Hims & Hers’ product pipeline, and the partnership with Novo Nordisk provides a tangible narrative for investors to rally around. Although the stock remains down 3% year-to-date, the recent uptick appears to be part of a recovery effort. However, the rapid ascent raises questions about whether the market has jumped the gun before the actual earnings figures are released.
The Impact of the Novo Nordisk Partnership
Hims & Hers and Novo Nordisk have had a complicated relationship. The company had previously reported ongoing discussions regarding the distribution of Wegovy injections and oral Wegovy through its platform, with implementation projected for Q3 2025. The establishment of a favorable partnership alters this landscape significantly.
This partnership is crucial for several reasons. Hims & Hers has invested heavily in developing over 1 million square feet of U.S. facility space, including sterile injectable capacity tailored for weight management and hormonal support. Partnering with Novo Nordisk to distribute Wegovy enhances the company’s standing in the GLP-1 market, allowing it to differentiate itself from competitors that rely solely on compounded treatments. For investors wary of regulatory risks in compounding, the partnership with Novo Nordisk serves as a vital safety net.
Novo Nordisk is currently facing its own challenges, with its shares down 21% year-to-date due to pricing pressures and increasing competition in the market. A telehealth distribution partnership enables Novo Nordisk to connect directly with patients, presenting a strong incentive for both parties to develop a successful collaboration.
Growing Optimism Around Peptide Drugs
As noted in recent discussions, Wall Street’s positive sentiment regarding peptide drugs has been gaining traction. Hims & Hers has been focusing on building a peptide manufacturing facility in California, with plans to introduce a longevity specialty in 2026 that will incorporate peptides, coenzymes, and GLP/GIP treatments.
The company has already highlighted peptides as a key topic for its upcoming earnings call in November 2025, with significant trading activity indicating strong interest in this area. Regulatory clarity concerning peptide therapeutics could potentially unlock new revenue streams for Hims & Hers, which already caters to over 2.5 million subscribers.
Financial Outlook and Market Reactions
Hims & Hers has forecasted revenue for the next quarter to be between $600 million and $625 million, which is a solid projection. However, analysts predict an EPS of $0.06, reflecting a staggering 70% year-over-year decline, alongside expectations of adjusted EBITDA declining from previous levels.
This anticipated dip in profitability is not entirely unexpected. The company’s capital expenditures saw a remarkable rise of 138% year-over-year in Q4 2025, leading to negative free cash flow of -$2.57 million after a profitable prior year. Hims & Hers is making significant investments to enhance its manufacturing capabilities and expand its international presence, including the acquisition of Eucalyptus, which has an annual recurring revenue exceeding $450 million. Such aggressive spending, while beneficial for long-term growth, can compress margins in the near term.
The Upcoming Earnings Call
The earnings call on May 11 will serve as a critical juncture for Hims & Hers. Investors will be keen to see if the revenue aligns with the projected guidance and how management addresses the trajectory of EBITDA. Insights regarding the structure or timeline of the Novo Nordisk partnership could cause significant stock price fluctuations.
Optimists believe Hims & Hers is strategically pivoting towards branded GLP-1 distribution and peptide-based longevity care, with its subscriber base growing at a rate of 13% annually and monthly revenue per subscriber reaching $83. Conversely, skeptics point out that the stock has already experienced a substantial rise based on narrative momentum, entering a quarter where profitability could sharply decline.
Both perspectives hold merit as the upcoming earnings report may ultimately reveal the truth behind the current stock movement.
Key Takeaways
- Hims & Hers stock surged 9% amid investor enthusiasm for its peptide pipeline and Novo Nordisk partnership.
- The company is investing heavily in manufacturing and acquisitions, leading to projected EPS declines.
- The upcoming earnings call on May 11 will be pivotal in determining the stock’s trajectory and investor sentiment.
In conclusion, Hims & Hers stands at a crossroads. The interplay between strategic partnerships, market projections, and investor expectations will shape its future. As the company continues to navigate its growth phase, the May 11 earnings report could either validate the recent bullish sentiment or serve as a reality check for the market.
Read more → www.aol.com